13F filer · CIK 315066 ↗
Fidelity Investments
You are looking at Q3 2016. See the latest, Q2 2026 →
Reported value
$750.86B
+2.5% on the quarter before
Positions
2,646
169 new · 170 sold out
Top 10
15.7%
of the value
Est. gain
+$35.38B
on stocks held all quarter
Est. return
+5.3%
on those stocks since Q2 2016
Positions as of Sep 30, 2016, from Fidelity Investments's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
The 24 largest positions, 25% of the reported value, each sized by its share, colored by what the fund did with it since Q2 2016. Striped tiles are options.
Largest buys
Since Q2 2016, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Apple~$2.94BAdded · 1.8% → 2.4%+25,965,309 shares
- Microsoft~$1.82BAdded · 0.9% → 1.2%+31,579,512 shares
- Fortive Corp~$1.24BAdded · 0.0% → 0.2%+24,289,454 shares
- Allergan Plc~$750.9MAdded · 0.4% → 0.5%+3,260,354 shares
- Alexion Pharmaceuticals Inc~$745.5MAdded · 0.3% → 0.4%+6,083,986 shares
- Amgen Inc~$710.4MAdded · 0.7% → 0.8%+4,258,696 shares
- Qualcomm~$604.8MAdded · 0.4% → 0.6%+8,828,642 shares
- Williams Companies~$502.1MAdded · 0.2% → 0.3%+16,338,119 shares
- Transcanada Corp~$474.9MAdded · 0.0% → 0.1%+9,998,082 shares
- Intuitive Surgical~$458.3MAdded · 0.2% → 0.3%+632,344 shares
Largest sells
Since Q2 2016, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Gilead Sciences Inc~$1.92BCut · 0.8% → 0.5%−24,318,779 shares
- E M C Corp Mass~$1.56BSold out · 0.2% → 0.0%−57,484,381 shares
- Mcdonalds Corp~$946.1MCut · 0.2% → 0.1%−8,201,631 shares
- Medivation Inc~$935.6MSold out · 0.1% → 0.0%−15,516,301 shares
- Celgene Corp~$908.2MCut · 0.4% → 0.3%−8,688,747 shares
- Coca Cola Co~$729.5MCut · 0.6% → 0.4%−17,236,946 shares
- Meta~$713.5MCut · 2.3% → 2.4%−5,562,385 shares
- IBM~$712.8MCut · 0.2% → 0.1%−4,487,423 shares
- Danaher Corp Del~$681.9MCut · 0.5% → 0.3%−8,698,608 shares
- Johnson & Johnson~$646.4MCut · 0.7% → 0.6%−5,472,095 shares
Holdings
As of Sep 30, 2016. Changes are in shares against Jun 30, 2016, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AppleCOM · shares +19% · price +18.3% | 2.4% | $18.30B | +$2.37B | ||||||||
| MetaCL A · shares −3.8% · price +12.2% | 2.4% | $18.26B | +$1.99B | ||||||||
| AmazonCOM · shares +1.6% · price +17.0% | 2.2% | $16.64B | +$2.38B | ||||||||
| AlphabetCAP STK CL A · shares −0.7% · price +14.3% | 2.0% | $14.74B | +$1.84B | ||||||||
| AlphabetCAP STK CL C · shares −2.0% · price +12.3% | 1.6% | $11.80B | +$1.29B | ||||||||
| MicrosoftCOM · shares +25% · price +12.6% | 1.2% | $9.20B | +$824.1M | ||||||||
| Visa Inc.COM CL A · shares −1.7% · price +11.5% | 1.1% | $8.60B | +$886.9M | ||||||||
| Unitedhealth Group IncCOM · shares +2.3% · price −0.8% | 1.0% | $7.74B | −$64.8M | ||||||||
| Medtronic PlcSHS · shares −0.9% · price −0.4% | 0.87% | $6.51B | −$27.9M | ||||||||
| SalesforceCOM · shares −9.0% · price −10.2% | 0.86% | $6.46B | −$731.5M | ||||||||
| Berkshire Hathaway Inc DelCL A · shares −0.1% · price −0.3% | 0.84% | $6.31B | −$22.0M | ||||||||
| Amgen IncCOM · shares +13% · price +9.6% | 0.81% | $6.11B | +$474.8M | ||||||||
| NvidiaCOM · shares −0.6% · price +45.8% | 0.73% | $5.46B | +$1.71B | ||||||||
| Jpmorgan Chase & CoCOM · shares −3.1% · price +7.2% | 0.72% | $5.39B | +$359.9M | ||||||||
| Wells Fargo & Co NewCOM · shares −3.6% · price −6.4% | 0.69% | $5.20B | −$358.3M | ||||||||
| Activision Blizzard IncCOM · shares +5.6% · price +11.8% | 0.66% | $4.93B | +$491.9M | ||||||||
| Home Depot IncCOM · shares −9.0% · price +0.8% | 0.64% | $4.81B | +$37.0M | ||||||||
| Chevron Corp NewCOM · shares −7.4% · price −1.8% | 0.63% | $4.75B | −$88.2M | ||||||||
| MastercardCL A · shares −7.6% · price +15.6% | 0.62% | $4.66B | +$628.4M | ||||||||
| QualcommCOM · shares +15% · price +27.9% | 0.60% | $4.51B | +$850.8M | ||||||||
| Johnson & JohnsonCOM · shares −13% · price −2.6% | 0.60% | $4.48B | −$120.3M | ||||||||
| Starbucks CorpCOM · shares −9.3% · price −5.2% | 0.59% | $4.45B | −$245.0M | ||||||||
| Citigroup IncCOM NEW · shares −2.9% · price +11.4% | 0.57% | $4.26B | +$436.9M | ||||||||
| Boston Scientific CorpCOM · shares −0.6% · price +1.8% | 0.57% | $4.24B | +$76.7M | ||||||||
| TeslaCOM · shares −6.1% · price −3.9% | 0.53% | $3.97B | −$160.6M | ||||||||
| Total · 2,646 positions | 100% | $750.86B | +$35.38B |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q2 2016 to Q3 2016: 2,417 stocks held throughout, up $35.38B (+5.3%).
- Amazon+$2.38B+17%
- Apple+$2.37B+18%
- Meta+$1.99B+12%
- Alphabet+$1.84B+14%
- Nvidia+$1.71B+46%
- Teva Pharmaceutical Inds Ltd−$285.1M−8%
- Wells Fargo & Co New−$358.3M−6%
- Danaher Corp Del−$617.0M−22%
- Salesforce−$731.5M−10%
- Bristol Myers Squibb Co−$919.1M−27%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out, 6 splits read into the share counts.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | $2.30T+21% | SEC ↗ |
| Q1 2026 | May 15, 2026 | $1.90T−3% | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | $1.96T+2% | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | $1.92T+8% | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | $1.77T+13% | SEC ↗ |
| Q1 2025 | May 12, 2025 | $1.57T−7% | SEC ↗ |
| Q4 2024 | Feb 13, 2025 | $1.68T+2% | SEC ↗ |
| Q3 2024 | Nov 13, 2024 | $1.64T+5% | SEC ↗ |
| Q2 2024 | Aug 13, 2024 | $1.56T+5% | SEC ↗ |
| Q1 2024 | May 13, 2024 | $1.49T+14% | SEC ↗ |
| Q4 2023 | Feb 13, 2024 | $1.30T+13% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.16T−3% | SEC ↗ |
| Q2 2023 | Aug 11, 2023 | $1.19T−45% | SEC ↗ |
| Q1 2023 | May 11, 2023 (amended) | $2.19T+117% | SEC ↗ |
| Q4 2022 | Feb 13, 2023 | $1.01T+5% | SEC ↗ |
| Q3 2022 | Nov 10, 2022 | $958.93B−4% | SEC ↗ |
| Q2 2022 | Aug 12, 2022 | $1.00T−20% | SEC ↗ |
| Q1 2022 | May 13, 2022 | $1.25T−8% | SEC ↗ |
| Q4 2021 | Feb 14, 2022 | $1.35T+7% | SEC ↗ |
| Q3 2021 | Feb 14, 2022 (amended) | $1.26T−1% | SEC ↗ |
| Q2 2021 | Aug 13, 2021 | $1.28T+9% | SEC ↗ |
| Q1 2021 | May 14, 2021 | $1.17T+4% | SEC ↗ |
| Q4 2020 | Feb 8, 2021 | $1.12T+14% | SEC ↗ |
| Q3 2020 | Nov 13, 2020 | $989.33B+9% | SEC ↗ |
| Q2 2020 | Aug 24, 2020 (amended) | $909.48B+26% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $722.13B−20% | SEC ↗ |
| Q4 2019 | Feb 7, 2020 | $906.40B+9% | SEC ↗ |
| Q3 2019 | Nov 13, 2019 | $833.77B−3% | SEC ↗ |
| Q2 2019 | Aug 13, 2019 | $856.19B+3% | SEC ↗ |
| Q1 2019 | May 13, 2019 (amended) | $834.93B+14% | SEC ↗ |
| Q4 2018 | Feb 13, 2019 (amended) | $730.25B−18% | SEC ↗ |
| Q3 2018 | Nov 9, 2018 | $888.88B+2% | SEC ↗ |
| Q2 2018 | Aug 10, 2018 (amended) | $868.68B+3% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $842.35B−1% | SEC ↗ |
| Q4 2017 | Feb 12, 2018 | $853.06B+3% | SEC ↗ |
| Q3 2017 | Nov 13, 2017 | $827.12B+3% | SEC ↗ |
| Q2 2017 | Aug 29, 2017 (amended) | $804.55B+2% | SEC ↗ |
| Q1 2017 | May 11, 2017 | $787.10B+5% | SEC ↗ |
| Q4 2016 | Feb 10, 2017 (amended) | $748.25B−0% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 | $750.86B+2% | SEC ↗ |
| Q2 2016 | Aug 11, 2016 | $732.58B+1% | SEC ↗ |
| Q1 2016 | May 16, 2016 | $722.80B | SEC ↗ |